
Reddit Agrees, the '137 Club' Is the Best Way to Make Steak. Here's How It Works
One curious phenomenon has commenters proclaiming that 137 degrees Fahrenheit is the best temperature for cooking steak sous vide. The cooking hack allegedly yields the best flavor and texture. Ribeye is the most common cut in many discussions, but I've seen recommendations on cheaper cuts of beef like chuck steak and New York strip. A Reddit search reveals over 125 threads on the aptly named "137 Club." So I dug deeper to look at the science behind this cooking trend and, of course, tried it for myself.
The science of cooking the perfect steak
I seasoned every steak identically with salt, granulated garlic powder and cracked black pepper.
John Carlsen/CNET
Ahead of my test, I hit the books. My first instinct was to consult Modernist Cuisine by Nathan Myhrvold, Chris Young and Maxine Bilet, which is one of the most comprehensive resources on the science of cooking.
With a list price that usually tops $500, over 2,400 pages across six volumes and no digital version, this is easier said than done. Fortunately, I found a copy of the more compact Modernist Cuisine at Home in Brigham Young University's collection near my home. ("More compact" is a relative term since it's also huge.) Thankfully, Modernist Cuisine at Home has an entire section about cooking steak, including the sous vide method.
Vacuum sealing the steaks overnight allowed the seasoning to work as a marinade.
John Carlsen/CNET
The book groups cuts of steak into two categories: tender (filet, tenderloin, New York strip, ribeye, T-bone and so on) and tough cuts (chuck, skirt, hanger, flat iron, flank and so on). Tender cuts typically cook at lower temperatures, with the authors and their lab generally preferring a medium rare doneness around 133 F in most cases. In contrast, the recommendations for tough cuts hover around 144 F to 149 F, which the book implies is a more traditional roast-like result: think tender and flaky rather than extra juicy.
Douglas Baldwin's masterclass A Practical Guide to Sous Vide Cooking, cites multiple scientific papers that suggest the best tenderness results with beef lie somewhere between 120 F and 150 F, with specific mention of 131 F to 140 F for cheaper, tougher cuts of beef. This appears to be the sweet spot for converting tough collagen into smooth, flavorful gelatin.
Additionally, Modernist Cuisine at Home suggests that ribeye, a tender cut of meat, turns out best after three hours at 133 F. There are small differences between the resources, but both seem to validate the 137 Club as a catchall method for steak.
The steaks barely fit in the container I use for my sous vide bath, but I made it work with some strategic spacers and weights.
John Carlsen/CNET
While I wasn't able to track down the founding member of the 137 Club, I know that the term started gaining steam in April 2020, at least on Reddit.
If I had to guess why 137 F became the magic number, it probably comes down to preference for the first person who tried it -- they might have liked it more medium than medium rare. After all, 137 degrees falls in the aforementioned temperature range, with a margin of error in case the temperature of the sous vide bath fluctuates during cooking. In this case, the temperature could vary by 3 degrees either way without affecting the results too heavily.
My research ends here, but I doubt I'll be the last person wondering where it all came from.
The experiment
We all tried three samples with a simple survey asking about the texture, flavor and anything else that stood out.
John Carlsen/CNET
Now that we know that there's some science behind the 137 Club, it's time to test. I originally intended to test it with ribeye, which frequently comes up in 137 Club threads. It has a great balance of fatty tissue that supposedly renders better at a higher temperature. Instead, I found tender 1-inch T-bones on sale, which will work just fine.
The main purpose was to see if there were any noticeable differences in the cooking. There were five taste testers: myself and four others who I'll refer to as Annette, Lauren, Hank and Nora. None of us had tasted the 137 F method before.
Steak A: Grilled
This was also the fastest cook because it required practically no additional prep beyond seasoning.
John Carlsen/CNET
I grilled Steak A in the traditional style, using a timer and a meat thermometer to reach an internal temperature of 131 F. (I aimed for 129 F, but grills are fickle things.) It took about 7 minutes.
All of us agreed the traditional grilled steak was the least tender of the three steaks. As expected, the inside of the steak wasn't as consistent as with the sous vide steaks. However, it was juicy and the outside seared perfectly because I didn't have to worry as much about ruining the sous vide steaks. Nora even said it was her favorite: "Most flavor, I can taste each seasoning."
Steak B: Sous vide at 129 F for 60 minutes
I learned to sous vide steak at 129 F, so it was a good comparison point.
John Carlsen/CNET
I cooked Steak B with my normal sous vide method of 129 F for 60 minutes. (Note: I usually do 120 minutes, but shortened it due to time constraints.) Crucially, this steak lies outside the temperature range mentioned earlier. Since the experiment was at a family member's house, I chose to sear the sous vide steaks on the grill, which isn't as precise or powerful as my trusty blowtorch.
Also, searing multiple T-bones with my small blowtorch would've taken an eternity. Likewise, I could've done a better job by not searing all three sous vide steaks at the same time.
I bought four steaks in total, so there were two Steak Bs, with the thinner one turning out slightly more medium after searing.
John Carlsen/CNET
As a result, Steak B's crust was uneven and the flavor wasn't as pronounced as the grilled steak. The fat also didn't render as well as the other steaks. Everyone liked how soft this steak was, with one tester saying it fell apart in her mouth. Still, Steak B was the favorite option of three tasters: Annette, Lauren and me.
However, it was the lowest-ranked steak for the other two respondents. Hank said it was "a little too different for my liking but still enjoyable." Meanwhile, Nora simply liked it but wrote "would not order again." I'll try not to take it personally.
Steak C: Sous vide at 137 F for 60 minutes (also known as the 137 Club)
In my case, I feel like it was a toss-up between Steak B (middle) and Steak C (left).
John Carlsen/CNET
I cooked Steak C at 137 F for an hour before keeping it warm in the 129 F bath with Steak B for another hour. Yes, the extra time affected the final result on Steak C, but seeing that many 137 Club threads suggest cooking for at least 120 minutes, I was fine adding a little more time. The sear turned out a little better than with Steak B.
We all noticed that it wasn't as moist as the other sous vide steak, but it was extremely juicy. However, Steak C was flakier, more tender and seemed to have a deeper flavor because the fat had more time to render out and interact with the meat. Juiciness was the deciding factor for the tasters who preferred the other sous vide steak. But Steak C certainly had fans and was very good, with Hank saying it was "the best of the three in my opinion."
What's the verdict on the 137 Club?
Despite juggling cooking times and completing three steak methods simultaneously, it's always so rewarding to share good food with family.
John Carlsen/CNET
I learned two things from this experiment. First, sous vide steaks cooked at 137 F are just as delicious as other methods. It also seems to render fat more effectively than lower sous vide temperatures with a slightly higher level of doneness. It's ideal when you have a few hours to let the water bath work its magic. This helps balance out some of the confirmation bias of the many positive sentiments on Reddit.
Secondly, whether anyone likes the final result ultimately reflects their personal preferences and that's fine. While medium rare is very popular for a lot of people, there are individuals -- my wife included -- who prefer medium-well and well-done steaks. (In case you're wondering, she says well-done sous vide steaks are delicious and much more forgiving than on the grill.)
A final bonus lesson is something I've experienced many times -- it's a blast to experiment when you find something interesting that's within your skills. Trying one thing doesn't mean giving up a treasured cooking method or a favorite meal, but it can open up your possibilities and help you find new ways to make great food.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
27 minutes ago
- CBS News
Kids impacted by pediatric cancer get MLB star treatment with help from White Sox
Some special kids got to feel what it's like to be a baseball player. The kids, who are impacted by cancer, swapped roles and signed trading cards and baseballs for White Sox players. Inside Rate Field at the Wintrust Scout Lounge, some of the softest spoken voices are making a major impact. "Today was very cool," Ryan Block said. Block, 11, is one of 15 kids from the local non-profit organization, Cal's Angels. "We try to normalize their treatment and their life as much as possible," coordinator Megan Gertz said. The kids were impacted by pediatric cancer. They shared custom-designed trading cards with their faces on them with coaches and players, like pitcher Drew Thorpe. "We go through our day-to-day lives as Major League Baseball players. Just kind of the flip side of it. Like It's cool for them to kind of feel how we feel sometimes," he said. "It's usually they sign our stuff because they're the famous, popular people and we're just like, some kids," Block said. But they're not just some kids. Block was diagnosed with Burkitt's leukemia, a very rare and aggressive form of leukemia, but two years ago, his doctors did a scan and found his body was clear of cancer. "I had my hair, and then I lost it. Then I was like sick, I didn't feel good. I lost like a lot of weight," he said. Cal's Angels said the reverse signing aims to build confidence and celebrate their everyday battle against cancer. "We're six years later from when he first got sick, and we're here, which says something about the organization," Dan McCarthy said. He said his son, 8-year-old James, got sick right before he turned two in 2018. He was on the ventilator for about a month and a half and was in and out of Lurie Children's Hospital for three years. James was diagnosed with JMML, a very rare and aggressive form of leukemia. He's now in remission. "We kind of feel like we're on the other side of it now and he's doing really well," McCarthy said. His son is a man of few words, but he had this to say about the experience. "very, very cool," James said. The organization said next month is Pediatric Cancer Awareness Month. They plan to partner with schools, youth organizations, and businesses to wear gold and have gold ribbons throughout the Chicago area.


CNN
29 minutes ago
- CNN
New ‘Make America Healthy Again' report to be released in weeks
Food & healthFacebookTweetLink Follow Americans will have to wait several weeks for the Trump administration's next steps in its agenda to 'Make America Healthy Again,' according to three people familiar with the matter. While President Donald Trump's MAHA Commission will submit its strategy to the White House on Tuesday — sticking to an executive-ordered deadline — scheduling issues stand in the way of its public release. The commission is 'on track' to deliver its report to the White House by August 12, White House spokesman Kush Desai said in a statement. 'The report will be unveiled to the public shortly thereafter as we coordinate the schedules of the President and the various cabinet members who are a part of the Commission.' Officials are aiming to launch their strategy by the end of this month, according to the three people familiar. The commission's first MAHA report, issued in May, laid out the case that ultraprocessed foods, pharmaceutical prescriptions and environmental toxins are driving a crisis of childhood chronic disease in America. Much of the reports' findings echoed longtime arguments of health secretary Robert F. Kennedy Jr., who leads the commission. The second installment is expected to propose strategies and reforms to tackle those issues. Actions can include, per the president's executive order, ending certain federal practices that 'exacerbate the health crisis' and 'adding powerful new solutions.' Public health experts, MAHA supporters and industry advocates alike have been anxiously awaiting the commission's recommendations, and how far they will go. There is lingering unease among farmers and agricultural groups after the first report flagged studies that suggest links between commonly used pesticides and various illnesses such as cancer and liver problems. Groups like the American Farm Bureau Federation called those 'unproven theories' and warned that calling use of common pesticides into question could jeopardize Americans' confidence in the food supply. Federal health and agricultural officials sought to reassure farmers in the ensuing weeks. This month, a high-ranking Enviornmental Protection Agency official told attendees at a sugar industry conference that agencies would 'respect' the current regulatory framework, as reported by DTN Progressive Farmer, an agriculture news and analysis company. Another potential battleground is the federal path forward on ultraprocessed foods. Kennedy has led a public campaign for major food brands to voluntarily remove artificial additives and dyes from popular products, but nutrition advocates have pushed for the administration to crack down with regulations. This month, a former leader of the US Food and Drug Administration challenged the agency to remove ultraprocessed foods from the market by essentially outlawing certain ingredients. But some have remained skeptical that federal MAHA leaders will take drastic action. 'We need policies to change big food and the food system, so it produces healthier foods,' Jim Krieger, executive director of Healthy Food America, said in a news briefing Monday. 'Will [the MAHA commission] move beyond PR efforts, voluntary agreements and handshakes — none of which have really worked to improve the food system in the past — and suggest regulatory action with real teeth?'
Yahoo
an hour ago
- Yahoo
IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies
The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a strong pipeline of clinical trials, and growing regulatory approvals. Leading companies such as GlaxoSmithKline, Mirum Pharmaceuticals, Ipsen Pharma, Albireo, Takeda, and others are actively developing IBAT inhibitor therapies targeting conditions like PBC, PSC, ALGS, PFIC, and related diseases. LAS VEGAS, Aug 11, 2025 /PRNewswire/ -- DelveInsight's IBAT Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), metabolic dysfunction-associated steatohepatitis (MASH), chronic constipation, biliary atresia, Alagille syndrome (ALGS), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging IBAT inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the IBAT Inhibitors Market Report As per DelveInsight's analysis, the total market size of IBAT inhibitors in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), metabolic dysfunction-associated steatohepatitis (MASH), chronic constipation, biliary atresia, Alagille syndrome (ALGS), and others. Leading IBAT inhibitor companies, such as GlaxoSmithKline, Mirum Pharmaceuticals, Ipsen, Albireo, and others, are developing novel IBAT inhibitors that can be available in the IBAT inhibitors market in the coming years. Some of the key IBAT inhibitors in the pipeline include Linerixibat, Volixibat, Ritivixibat, and others. In March 2025, Takeda announced that Japan's MHLW approved LIVMARLI Oral Solution 10 mg/mL for the treatment of pruritus associated with cholestasis in ALGS and PFIC. In November 2024, Ipsen announced data at the AASLD assessing the long-term efficacy and safety of patients treated with BYLVAY from two Phase III open-label extension studies in PFIC and ALGS. In October 2024, Mirum Pharmaceuticals announced that the FDA granted a breakthrough therapy designation (BTD) to volixibat as a possible treatment for cholestatic pruritus in patients with PBC. Volixibat also received FTD from the FDA in 2016 for the treatment of NASH in patients with liver fibrosis. Discover which indication is expected to grab the major IBAT inhibitors market share @ IBAT Inhibitors Market Report IBAT Inhibitors Market Dynamics The market dynamics for IBAT inhibitors are shaped by a confluence of factors, including rising prevalence of rare cholestatic liver diseases, growing awareness of pediatric liver disorders, and the increasing regulatory support for rare disease therapeutics. The approval of two key drugs, LIVMARLI and BYLVAY, by the US FDA and European regulatory authorities has not only validated the therapeutic mechanism but also catalyzed investment and R&D activity in this niche segment. The market is expected to witness significant growth due to the unmet medical need in pediatric hepatology and the relatively limited competition within this orphan drug space. Both LIVMARLI and BYLVAY have demonstrated clinically meaningful reductions in pruritus and improvements in liver function biomarkers, supporting their adoption. Furthermore, these drugs benefit from orphan drug designation, which grants market exclusivity, reduced regulatory fees, and extended patent life, enhancing the commercial attractiveness for developers. Their use is currently being explored in additional indications, including biliary atresia and intrahepatic cholestasis of pregnancy, which could further expand their market potential. Despite the momentum, there are key challenges that could moderate growth. One is the high cost of therapy, which may limit access in markets with less robust healthcare reimbursement systems. Additionally, the rarity of target diseases necessitates specialized diagnostic capabilities and referral networks, which are underdeveloped in many regions. Market penetration in emerging economies remains limited, creating a disparity in treatment availability. Moreover, competition is expected to intensify as more players enter the space with either me-too IBAT inhibitors or gene therapy-based solutions aiming at disease modification. IBAT Inhibitors Treatment Market As of now, two IBAT inhibitors, LIVMARLI and BYLVAY (also marketed as KAYFANDA), have received regulatory approvals. LIVMARLI, an oral IBAT inhibitor available in both liquid and tablet forms, has been approved by the U.S. FDA for use in pediatric patients with cholestatic liver diseases. In the U.S., it is indicated for treating cholestatic pruritus in patients with Alagille syndrome (ALGS) aged three months and older, and in Europe for those aged two months and older. Additionally, it is approved in the U.S. for patients aged 12 months and older with progressive familial intrahepatic cholestasis (PFIC), and in Europe for patients aged three months and above. The drug is currently being studied in the Phase III EXPAND trial to assess its potential in broader settings of cholestatic pruritus, with enrollment expected to conclude by 2026. LIVMARLI has received Breakthrough Therapy designation in the U.S. for ALGS and PFIC2, and Orphan Drug Designation (ODD) for both ALGS and PFIC in the U.S. and Europe. Japan's Ministry of Health, Labour and Welfare (MHLW) granted it ODD for anticipated indications in ALGS and PFIC in December 2022. In April 2025, Mirum Pharmaceuticals announced FDA approval of a new tablet formulation of LIVMARLI for use in ALGS and PFIC, with commercial availability expected in June 2025 via the Mirum Access Plus program. Additionally, in November 2024, the company presented new clinical data on LIVMARLI at the AASLD Liver Meeting. BYLVAY is a potent, once-daily IBAT inhibitor that works locally in the small intestine with limited systemic absorption. It is approved in the U.S. for treating pruritus in PFIC patients aged three months and older, where it benefits from orphan drug exclusivity. First launched in the U.S. in 2021 for PFIC, BYLVAY is supported by programs to facilitate patient access and support. In the EU, it is approved for PFIC in children aged six months and above and is available in over nine countries, with reimbursement in key markets such as Germany, France, Italy, the UK, and Belgium. In June 2023, the U.S. FDA approved BYLVAY for treating cholestatic pruritus in ALGS patients aged 12 months and older. Subsequently, in September 2024, the European Commission approved the drug, under the brand name KAYFANDA, under exceptional circumstances for treating cholestatic pruritus in ALGS in children aged six months and above. Learn more about the IBAT inhibitors @ IBAT Inhibitors Analysis Key Emerging IBAT Inhibitors and Companies Key IBAT inhibitors in the pipeline include Volixibat (Mirum Pharmaceuticals), Linerixibat (GlaxoSmithKline), Ritivixibat (Ipsen/Albireo), and others. Volixibat is an orally administered, minimally absorbed drug designed to specifically block the ileal bile acid transporter (IBAT). By inhibiting IBAT, it disrupts the enterohepatic circulation of bile acids, potentially lowering bile acid levels in the liver and bloodstream—offering a novel treatment strategy for adult cholestatic liver diseases. The drug is currently being tested in Phase IIb trials: the VISTAS study for primary sclerosing cholangitis (PSC) and the VANTAGE study for primary biliary cholangitis (PBC). According to Mirum Pharmaceuticals' 2024 annual report, enrollment in the VISTAS study for PSC is expected to conclude in the second half of 2025, with top-line results anticipated in 2026. Enrollment for the VANTAGE study in PBC is projected to be completed in 2026. In November 2024, Mirum presented data on volixibat at the AASLD meeting. Linerixibat, another IBAT inhibitor, is an orally administered therapy under development for managing cholestatic pruritus linked to PBC, a rare autoimmune liver disorder. By blocking the reabsorption of bile acids, linerixibat aims to tackle the underlying mechanism of itch in these patients. Both the U.S. FDA and the European Medicines Agency (EMA) have granted orphan drug designation (ODD) to linerixibat for this indication. In November 2024, GSK reported positive top-line results from GLISTEN, its global Phase III trial assessing linerixibat in adults with PBC-related cholestatic pruritus. According to GSK's Q4 update, regulatory submissions in the U.S., Europe, and China are expected in the first half of 2025, followed by a U.S. regulatory decision and a Japan submission in the second half of the year. Regulatory decisions in Europe, Japan, and China are projected for 2026. The anticipated launch of these emerging therapies are poised to transform the IBAT inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the IBAT inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about IBAT inhibitors clinical trials, visit @ IBAT Inhibitors Treatment IBAT Inhibitors Overview IBAT inhibitors are typically taken orally, with most designed to remain in the gut and exhibit minimal absorption into the bloodstream. As a result, plasma levels often remain below detectable limits after either single or repeated dosing within the approved range. Nonetheless, newer IBAT inhibitors that are systemically absorbed are currently under development. A key drawback of gut-restricted IBAT inhibitors is their reduced effectiveness in patients with complete or near-total biliary obstruction, where bile acids do not adequately reach the small intestine. This is especially a concern in children, as biliary atresia is the leading cause of cholestasis in this population. To address this, systemically active ASBT inhibitors have been created. ASBTs are also found in the proximal tubules of the kidneys, where they help reabsorb small amounts of bile acids filtered through the glomerulus. IBAT Inhibitors Epidemiology Segmentation The IBAT inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for IBAT Inhibitors Total Eligible Patient Pool in Selected Indications for IBAT Inhibitors Total Treated Cases in Selected Indications for IBAT Inhibitors IBAT Inhibitors Report Metrics Details Study Period 2020–2034 IBAT Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), metabolic dysfunction-associated steatohepatitis (MASH), chronic constipation, biliary atresia, Alagille syndrome (ALGS), and others Key IBAT Inhibitors Companies GlaxoSmithKline, Mirum Pharmaceuticals, Ipsen, Albireo, Takeda, Ipsen Pharma, and others Key IBAT Inhibitors Linerixibat, Volixibat, Ritivixibat, LIVMARLI, BYLVAY/KAYFANDA, and others Scope of the IBAT Inhibitors Market Report IBAT Inhibitors Therapeutic Assessment: IBAT Inhibitors' current marketed and emerging therapies IBAT Inhibitors Market Dynamics: Conjoint Analysis of Emerging IBAT Inhibitor Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, IBAT Inhibitors Market Access and Reimbursement Discover more about IBAT inhibitors in development @ IBAT Inhibitors Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology Market Forecast Methodology of IBAT Inhibitors 6 IBAT Inhibitors Market Overview at a Glance in the 7MM 6.1 Market Share (%) Distribution by Therapies in 2025 6.2 Market Share (%) Distribution by Therapies in 2034 6.3 Market Share (%) Distribution by Indications in 2025 6.4 Market Share (%) Distribution by Indications in 2034 7 IBAT Inhibitor: Background and Overview 7.1 Introduction 7.2 The potential of IBAT inhibitors in Different Indications 7.3 Clinical Applications of IBAT Inhibitors 8 Target Patient Pool 8.1 Key Findings 8.2 Assumptions and Rationale: 7MM 8.3 Epidemiology Scenario in the 7MM 8.3.1 Total Cases in Selected Indications for IBAT Inhibitor in the 7MM 8.3.2 Total Eligible Patient Pool in Selected Indications for IBAT Inhibitor in the 7MM 8.3.3 Total Treated Cases in Selected Indications for IBAT Inhibitor in the 7MM 8.4 The US 8.5 EU4 and the UK 8.6 Japan 9 Marketed Drugs 9.1 Key Competitors 9.2 LIVMARLI (maralixibat chloride): Mirum Pharmaceuticals 9.2.1 Product Description 9.2.2 Regulatory Milestones 9.2.3 Other Developmental Activities 9.2.4 Clinical Development 9.2.5 Safety and Efficacy 9.2.6 Analyst Views 10 Emerging Therapies 10.1 Key Cross Competition 10.2 Volixibat: Mirum Pharmaceuticals 10.2.1 Drug Description 10.2.2 Others Developmental Activities 10.2.3 Clinical Trials Information 10.2.4 Safety and Efficacy 10.2.5 Analyst's View 10.3 Linerixibat: GlaxoSmithKline List of drugs to be continued in the final report... 11 IBAT Inhibitor: the 7MM Analysis 11.1 Key Findings 11.2 Key Market Forecast Assumptions 11.2.1 Cost Assumptions and Rebates 11.2.2 Pricing Trends 11.2.3 Analogue Assessment 11.2.4 Launch Year and Therapy Uptakes 11.3 Market Outlook 11.4 Attribute Analysis 11.5 Total Market Size of IBAT Inhibitor in the 7MM 11.6 The US Market Size 11.6.1 Total Market Size of IBAT Inhibitor in the US 11.6.2 Market Size of IBAT Inhibitors by Indication in the United States 11.6.3 Market Size of IBAT Inhibitor by Therapies in the US 11.7 EU4 and the UK Market Size 11.8 Japan Market Size 11 Unmet Needs 12 SWOT Analysis 13 KOL Views 14 Market Access and Reimbursement 14.1 The US 14.2 EU4 and the UK 14.3 Japan 15 Acronyms and Abbreviations 16 Bibliography 17 Report Methodology Related Reports Metabolic Dysfunction-associated Steatohepatitis Market Metabolic Dysfunction-associated Steatohepatitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MASH companies, including Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Akero Therapeutics, 89bio, Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics, Lipocine, Viking Therapeutics, Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai), Hepion Pharmaceuticals, Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences, Ionis Pharmaceuticals, Corcept Therapeutics, among others. Primary Sclerosing Cholangitis Market Primary Sclerosing Cholangitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PSC companies, including Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, Inc., NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, among others. Primary Biliary Cholangitis Market Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PBC companies, including CymaBay Therapeutics, Zydus Therapeutics, Genfit, GlaxoSmithKline, Calliditas Therapeutics AB (Calliditas Therapeutics Suisse SA), Intercept Pharmaceuticals, Mirum Pharmaceuticals, Escient Pharmaceuticals, Gannex Pharma, Nanjing Chia-tai Tianqing Pharmaceutical, among others. Biliary Atresia Market Biliary Atresia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key biliary atresia companies, including Mirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data